21.60
-0.73 (-3.27%)
Previous Close | 22.33 |
Open | 22.01 |
Volume | 8,573,967 |
Avg. Volume (3M) | 15,478,015 |
Market Cap | 41,282,785,280 |
Price / Earnings (TTM) | 40.00 |
Price / Earnings (Forward) | 20.33 |
Price / Sales | 2.91 |
Price / Book | 4.64 |
52 Weeks Range | |
Earnings Date | 5 May 2025 - 9 May 2025 |
TTM Dividend Yield | 3.77% |
Profit Margin | 6.67% |
Operating Margin (TTM) | 23.43% |
Diluted EPS (TTM) | 0.540 |
Quarterly Revenue Growth (YOY) | -0.10% |
Quarterly Earnings Growth (YOY) | -10.40% |
Total Debt/Equity (MRQ) | 90.18% |
Current Ratio (MRQ) | 0.960 |
Operating Cash Flow (TTM) | 1.77 B |
Levered Free Cash Flow (TTM) | 1.62 B |
Return on Assets (TTM) | 6.88% |
Return on Equity (TTM) | 9.87% |
Market Trend
Short Term | Medium Term | ||
Industry | Household & Personal Products (US) | Bearish | Bearish |
Household & Personal Products (Global) | Bearish | Bearish | |
Stock | Kenvue Inc. | Bearish | Bullish |
AIStockmoo Score
Analyst Consensus | -0.5 |
Insider Activity | NA |
Price Volatility | -1.0 |
Technical Moving Averages | 1.0 |
Technical Oscillators | 0.0 |
Average | -0.13 |
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power. |
|
Sector | Consumer Defensive |
Industry | Household & Personal Products |
Investment Style | Mid Core |
% Held by Insiders | 0.04% |
% Held by Institutions | 102.09% |
52 Weeks Range | ||
Price Target Range | ||
High | 29.00 (Canaccord Genuity, 34.26%) | Buy |
Median | 23.75 (9.95%) | |
Low | 21.00 (UBS, -2.78%) | Hold |
Average | 24.19 (11.99%) | |
Total | 2 Buy, 6 Hold | |
Avg. Price @ Call | 22.30 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Barclays | 14 Apr 2025 | 22.00 (1.85%) | Hold | 22.71 |
27 Mar 2025 | 23.00 (6.48%) | Hold | 23.50 | |
Citigroup | 14 Apr 2025 | 22.00 (1.85%) | Hold | 22.71 |
Redburn Atlantic | 10 Apr 2025 | 23.50 (8.80%) | Hold | 21.87 |
Evercore ISI Group | 24 Mar 2025 | 25.00 (15.74%) | Hold | 23.37 |
Canaccord Genuity | 05 Mar 2025 | 29.00 (34.26%) | Buy | 23.04 |
07 Feb 2025 | 24.00 (11.11%) | Buy | 20.18 | |
Piper Sandler | 24 Feb 2025 | 27.00 (25.00%) | Buy | 23.30 |
UBS | 07 Feb 2025 | 21.00 (-2.78%) | Hold | 20.18 |
RBC Capital | 03 Feb 2025 | 24.00 (11.11%) | Hold | 21.23 |
No data within this time range.
TTM Dividend Yield | 3.77% |
2Y Average Dividend Yield | 2.83% |
Payout Ratio | 150.00% |
Expected Next Dividend Payment | May 2025 |
Ex Date | Announcement Date | Payment Date | Details |
---|---|---|---|
12 Feb 2025 | 16 Jan 2025 | 26 Feb 2025 | 0.205 Cash |
13 Nov 2024 | 17 Oct 2024 | 27 Nov 2024 | 0.205 Cash |
14 Aug 2024 | 25 Jul 2024 | 28 Aug 2024 | 0.205 Cash |
07 May 2024 | 25 Apr 2024 | 22 May 2024 | 0.2 Cash |
13 Feb 2024 | 25 Jan 2024 | 28 Feb 2024 | 0.2 Cash |
07 Nov 2023 | 26 Oct 2023 | 22 Nov 2023 | 0.2 Cash |
25 Aug 2023 | 20 Jul 2023 | 07 Sep 2023 | 0.2 Cash |
Annual Dividend Yield
Year | Annual Dividend ($) | Frequency/Year | Yield % |
---|---|---|---|
2025 | 0.205 | 1 | 0.95 |
2024 | 0.810 | 4 | 3.79 |
2023 | 0.400 | 2 | 1.86 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |